Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting

SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from...
May 12, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer

SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility...
May 05, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting

SALT LAKE CITY, May 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from...
May 02, 2017 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results

Third-Quarter 2017 Total Revenues of $196.9 MillionThird-Quarter 2017 GAAP Diluted EPS of $0.06 and Adjusted EPS of $0.27Company Increases Annual Revenue Guidance, Narrows Adjusted EPS Guidance SALT...
April 27, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment

SALT LAKE CITY and BOULDER, Colo., April 27, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration...
April 18, 2017 16:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017

SALT LAKE CITY, April 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with...
April 17, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database

SALT LAKE CITY, April 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data comparing BRCA1 and...
April 06, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s Novel PARP Inhibitor, BGB-290

SALT LAKE CITY, April 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has entered into a...
April 05, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Pivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scientific Publications

SALT LAKE CITY, April 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has published the third...
March 20, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting

SALT LAKE CITY, March 20, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company will present...